Verastem Oncology Names New CEO as Paterson Retires After 15 Years

  • Michael P. Bailey appointed CEO of Verastem Oncology effective January 1, 2027, succeeding Daniel Paterson.
  • Paterson retires after 15 years, including 4 as CEO, overseeing FDA approval of AVMAPKI FAKZYNJA CO-PACK.
  • Bailey brings 30 years of biopharma experience, including leadership roles at AVEO Pharmaceuticals and ImClone Systems.
  • VS-7375, an investigational KRAS G12D inhibitor, advances to Phase 2 trials across multiple tumor types.
  • Phase 3 trial for metastatic pancreatic cancer with VS-7375 expected to begin later in 2026.

Verastem Oncology's CEO transition comes at a critical juncture as the company seeks to expand its commercial footprint with AVMAPKI FAKZYNJA CO-PACK and advance its promising KRAS G12D inhibitor, VS-7375. The shift in leadership underscores the biopharma sector's emphasis on experienced executives to navigate complex clinical and regulatory landscapes. With Paterson's departure, the company loses a key figure who drove its first FDA approval, while Bailey's appointment signals a focus on leveraging his deep oncology drug development and commercialization background to sustain growth.

Leadership Transition
How Bailey's extensive oncology experience will shape Verastem's commercial and clinical strategies.
Clinical Pipeline
The pace at which VS-7375 advances through Phase 2 and into Phase 3 trials for pancreatic cancer.
Regulatory Milestones
Whether AVMAPKI FAKZYNJA CO-PACK meets confirmatory trial endpoints to secure continued FDA approval.